Following a primary degree in Biochemistry he undertook a PhD and post doctoral training at Queen’s in molecular enzymology.  In 2001, Chris was one of the founding members of QUB spinout company Fusion Antibodies Ltd., before returning to Queen’s in 2003 to take up an academic position.  

Chris is internationally renowned for his work in development of antibody and nanomedicine-based therapies for the treatment of cancer and other conditions. Work in his laboratory is funded by agencies such as Medical Research Council, US-Ireland, and various industrial sources such as AstraZeneca and Immunocore.

He also held a Royal Society Industrial Fellowship with GSK from 2012-15, and won the Vice Chancellor’s Prize for Innovation in 2015 with his group’s work on developing a novel nanomedicine for the treatment of sepsis and other inflammatory conditions. Chris is a member of the Medical Research Council Developmental Pathway Funding Scheme Panel.

Recently, Chris was awarded the prestigious APS Innovative Science Award recognising the significant contribution he has made to the pharmaceutical field over the course of his career.